Veracyte, Inc. reported financial results for the quarter ended June 30, 2026, announcing total revenue of $150.3 million, a 15% year-over-year increase driven by Decipher and Afirma testing growth. The company recorded GAAP net income of $25.5 million ($0.31 diluted EPS) and adjusted EBITDA of $44.0 million (29.2% margin). Veracyte raised its full-year 2026 revenue guidance to $590–$596 million, reflecting a 14–15% growth rate, while maintaining an adjusted EBITDA margin expectation above 26%. The company also launched the Prosigna LDT and TrueMRD for MIBC tests. Veracyte operates in the cancer diagnostics industry, providing molecular genomic tests to assess tumor biology.
